Log in

Tracker

Biotech class action and lawsuit tracker

Securities class actions, derivative suits, patent cases, settlements and SEC matters at public biotech and pharma companies, newest first, each from the company's own filings or court records.

Updated October 31, 2026. 153 entries. Download as CSV. Free to cite with a link to this page. All trackers.

DateCompanyTypeWhat happened
Alnylam Pharmaceuticals ALNYPatent caseAlnylam details Texas patent suit, two Cipla patent cases and a U.S. Attorney subpoena
Viking Therapeutics, Ligand Pharmaceuticals VKTXLGNDOther lawsuitViking and Ligand dispute VK2809 license termination in San Diego court
Viking Therapeutics VKTXOther lawsuitViking's ITC trade secret ruling against Ascletis is on appeal at Federal Circuit
Vanda Pharmaceuticals VNDAPatent caseCourt rules for Teva and Apotex in Vanda's HETLIOZ patent suits
Indivior Pharmaceuticals INDVSecurities class actionIndivior discloses Suboxone dental injury MDL of about 22,098 plaintiffs; no bellwether before 2028
Enanta Pharmaceuticals ENTAPatent caseEuropean patent court rules Enanta patent invalid in Paxlovid suit against Pfizer
Skye Bioscience SKYESecurities class actionSkye Bioscience faces nimacimab securities class action and two derivative suits
Skye Bioscience SKYESettlementSkye Bioscience faces October 2026 retrial of Cunning whistleblower suit
Amarin Corporation AMRNPatent caseAmarin settles Hikma patent and antitrust cases over generic Vascepa
Replimune Group REPLSecurities class actionReplimune 10-Q lists two Massachusetts securities class actions and consolidated derivative suits
Beta Bionics BBNXSecurities class actionBeta Bionics discloses securities class action over iLet statements
INTEGRA LIFESCIENCES HOLDINGS CORP IARTSecurities class actionIntegra LifeSciences details New Jersey class action and two derivative suits in 10-Q
CSL CSLSecurities class actionCSL faces shareholder class action over FY26 guidance and disclosure
Medpace Holdings MEDPSecurities class actionMedpace discloses plaintiff dropped Ohio securities class action over book-to-bill ratio
Labiana Health SA LABSettlementSomaLogic stockholder suit heads to 2027 trial without Standard BioTools; Palamedrix claim settled
Lifecore Biomedical LFCRSecurities class actionLifecore reports July hearing on securities class action settlement
Filana Therapeutics FLNASecurities class actionFifth Circuit vacates class certification in Filana securities class action
Curanex Pharmaceuticals CURXSecurities class actionCuranex discloses two New York class actions tied to its August 2025 IPO
Collegium Pharmaceutical COLLPatent caseCollegium settles Grünenthal patent suit over Nucynta ER generic for $17,000,000
Ultragenyx Pharmaceutical RAREPatent caseUltragenyx and Baylor settle Dojolvi patent litigation with Navinta, generic entry set for 2033
Supernus Pharmaceuticals SUPNSecurities class actionSupernus inherits Sage securities class action, derivative suits and SEC subpoena
Actinium Pharmaceuticals, Inc. (Delaware) ATNMSecurities class actionActinium securities class action dismissed with prejudice; plaintiffs file appeal
Jasper Therapeutics JSPRSecurities class actionJasper Therapeutics faced Oct 15 hearing on motion to dismiss briquilimab class action
Liquidia, United Therapeutics LQDAUTHRPatent caseLiquidia settles all patent and trade secret litigation with United Therapeutics
Xeris Biopharma Holdings XERSPatent caseXeris sues Torrent, Rising and others in New Jersey over generic Keveyis patent
Lunai Bioworks LNAIOther lawsuitWeird Science demands $10 million to end Delaware Chancery suit and other claims against Lunai
Lunai Bioworks LNAIOther lawsuitLunai Bioworks cites its Delaware suit against Seven Points Capital in Nasdaq trading halt request
Envoy Medical COCHMerger or deal suitEnvoy Medical ends Atlas SPAC redemption suit in Delaware with no payment
NEOGEN CORP NEOGSecurities class actionNeogen discloses appeal of dismissed Michigan securities suit and two related cases
Inovio Pharmaceuticals INOSecurities class actionInovio faces securities class action and five derivative suits over INO-3107 statements
Tonix Pharmaceuticals Holding TNXPPatent caseTonix gets Paragraph IV patent notice from Dr. Reddy's on generic TONMYA application
Lantheus Holdings LNTHMerger or deal suitLantheus discloses three stockholder suits over its Curium merger and 16 demand letters
Unicycive Therapeutics UNCYSecurities class actionUnicycive discloses another securities class action over its OLC application
Nektar Therapeutics NKTRSecurities class actionJury awards Nektar $90 million in Lilly contract case; securities class action pending
Sarepta Therapeutics SRPTSecurities class actionSarepta faces securities class action and five derivative suits over Elevidys disclosures
Aytu BioPharma AYTUPatent caseAytu BioPharma's Adzenys patent suit against Granules heads to a January 2027 trial
AnaptysBio ANABOther lawsuitAnaptysBio awaits post-trial argument in Delaware suit against GSK and Tesaro
Aquestive Therapeutics AQSTSecurities class actionAquestive faces securities class action and derivative suit over Anaphylm NDA statements
Beta Bionics BBNXSecurities class actionBeta Bionics discloses securities class action filed September 4, 2026 over iLet statements
Cardiff Oncology CRDFSettlementCardiff Oncology settles onvansertib license lawsuit with Nerviano Medical Sciences
ACADIA Pharmaceuticals ACADSecurities class actionAcadia derivative settlement gets preliminary approval as securities class action stays pending
Nutriband NTRBOther lawsuitNutriband says lawsuit over ended offering engagement remains in discovery
Abbott Laboratories ABTSettlementAbbott agrees to settle Gill case and preterm formula NEC claims for approximately $670 million
Mereo BioPharma Group MREOSecurities class actionMereo BioPharma faces securities class action naming its CEO and chief scientific officer
Outlook Therapeutics OTLKSecurities class actionOutlook Therapeutics faces securities class action and stayed derivative suit over LYTENAVA BLA
Exicure XCURSecurities class actionExicure's class action and derivative suits end with court-approved settlements
Neumora Therapeutics NMRASecurities class actionNeumora IPO class action over navacaprant disclosures awaits ruling on dismissal motion
GT Biopharma GTBPSettlementGT Biopharma sued by four convertible note holders over undelivered conversion shares
Vistagen Therapeutics VTGNSecurities class actionVistagen faces securities class action and two derivative suits over PALISADE-3 trial statements
HCW Biologics HCWBOther lawsuitHCW Biologics faces December jury trial in Florida mechanics lien foreclosure case
Scilex Holding SCLXPatent caseScilex loses ZTlido patent appeal as Federal Circuit affirms non-infringement ruling for Aveva
Scilex Holding SCLXOther lawsuitScilex and Semnur named in Sorrento equity holders' suit, now stayed in a California federal court
Capricor Therapeutics CAPRSecurities class actionCapricor discloses new securities class action and derivative suit as FDA date slips
Cytokinetics CYTKPatent caseCytokinetics sues Bristol-Myers Squibb and MyoKardia in Delaware patent suit over MYQORZO
Kyntra Bio KYNBSEC or regulatorKyntra Bio accrues $7.0 million for indemnity tied to SEC case against ex-CMO
Calidi Biotherapeutics CLDIOther lawsuitCalidi faces suits from two former finance staff and an investor's securities fraud claim
CorMedix CRMDSecurities class actionCorMedix faces DefenCath securities class action as derivative settlement heads to a hearing
Alumis ALMSSecurities class actionAlumis carries ACELYRIN securities class action over izokibep trial; dismissal motion pending
ARS Pharmaceuticals SPRYOther lawsuitARS Pharmaceuticals details Aptar trade secret suit and its own antitrust claim over neffy parts
ARS Pharmaceuticals SPRYSecurities class actionARS Pharmaceuticals faces securities class action over neffy insurance coverage timeline
Fate Therapeutics FATESecurities class actionFate Therapeutics faces securities class action and three derivative suits over Janssen disclosures
BioVie BIVIDerivative suitBioVie securities class certified in Nevada; three derivative suits stayed
Gossamer Bio GOSSSecurities class actionGossamer Bio faces securities class action; lead plaintiff named, amended complaint due Aug. 10
Alto Neuroscience ANROSecurities class actionAlto Neuroscience IPO securities class action dismissed with leave to amend
Inovio Pharmaceuticals INOOther lawsuitInovio's supply-contract suit against VGXI and GeneOne is set for trial in October 2026
Spero Therapeutics SPROSEC or regulatorSpero says SEC closed its investigation without action against it; two ex-executives settled
Humacyte HUMASecurities class actionHumacyte securities suit over Symvess safety enters discovery; four derivative suits pending
Atara Biotherapeutics ATRASecurities class actionAtara Biotherapeutics faces securities class action over tab-cel ALLELE study statements
Kyverna Therapeutics KYTXSecurities class actionKyverna faces IPO securities class action and consolidated derivative suit
Taysha Gene Therapies TSHADerivative suitTaysha derivative suit over 2023 private placement faces termination motion
TherapeuticsMD TXMDPatent caseTherapeuticsMD's Mayne Pharma suit is stayed; IMVEXXY patent cases against Teva and Sun continue
Erasca ERASSecurities class actionErasca faces securities class action and ERAS-0015 derivative suit
Bicara Therapeutics BCAXPatent caseBicara and Biocon face Y-Trap inventorship suit over ficerafusp alfa patents
Gain Therapeutics GANXOther lawsuitGain Therapeutics and CEO Gene Mack sued in Delaware over warrant exercise price
Veru VERUSecurities class actionVeru faces securities class action and five derivative suits over sabizabulin statements
Veru VERUOther lawsuitVeru faces fraud and warranty suit from the buyer of its FC2 business
Sana Biotechnology SANASecurities class actionSana Biotechnology securities class action is stayed after second amended complaint
Rocket Pharmaceuticals RCKTSecurities class actionRocket Pharmaceuticals faces securities class action and derivative suit over Danon trial
Metagenomi Therapeutics MGXSecurities class actionMetagenomi's IPO class action over Moderna collaboration disclosures moves into discovery
Axsome Therapeutics AXSMDerivative suitAxsome derivative suit dismissed in Delaware; New York case awaits ruling on motion
Axsome Therapeutics AXSMPatent caseAxsome resolves all Sunosi patent suits; Symbravo case against Apotex continues
MoonLake Immunotherapeutics MLTXSecurities class actionMoonLake faces securities class action over sonelokimab; motion to dismiss pending
CervoMed CRVOOther lawsuitCervoMed discloses ex-CEO's 2014 suit, narrowed in March, with trial set for October
Natera NTRAOther lawsuitNatera appeals Guardant false advertising judgment after $292.5 million verdict
Agenus AGENSecurities class actionAgenus securities class action dismissed, plaintiff appeals; SEC closes investigation
ANI Pharmaceuticals, CG Oncology ANIPCGONOther lawsuitANI loses post-trial motions in CG Oncology royalty case and defends Acella suit
ANI Pharmaceuticals ANIPPatent caseANI and Novitium face two generic drug patent suits and antitrust counterclaims in a third
Merck KGaA MRKSecurities class actionMerck faces securities class action over Gardasil demand in China, with derivative suits stayed
aTyr Pharma ATYRSecurities class actionaTyr Pharma moves to dismiss amended class action over efzofitimod statements
Ardelyx ARDXSecurities class actionArdelyx securities suit over Xphozah ends after appeal is withdrawn
Gilead Sciences GILDSettlementGilead HIV antitrust appeal awaits ruling after October 2025 argument; Aetna trial set for 2027
Gilead Sciences GILDSecurities class actionGilead cites August 2026 ruling in HIV drug injury suits with about 23,000 active plaintiffs
Iovance Biotherapeutics IOVASecurities class actionIovance faces securities class action and three derivative suits over 2025 revenue forecast
Iovance Biotherapeutics IOVADerivative suitIovance defends two Delaware derivative suits over director pay and a 2024 stock offering
Intellia Therapeutics NTLASecurities class actionIntellia says court dismissed securities class action; director pay and patent suits continue
Viatris VTRSSecurities class actionViatris faces Indore plant securities class action and derivative suits in two federal courts
Relay Therapeutics RLAYDerivative suitRelay Therapeutics is nominal defendant in Delaware derivative suit over 2021 to 2023 board pay
Puma Biotechnology PBYIPatent caseFederal Circuit affirms invalidity of Puma-licensed patents in Tagrisso suit against AstraZeneca
Puma Biotechnology PBYIOther lawsuitPuma's malpractice suit against former law firm waits on North Carolina Supreme Court
Ocugen OCGNSecurities class actionOcugen awaits Third Circuit ruling in dismissed securities suit as derivative suits remain stayed
Arcturus Therapeutics Holdings ARCTOther lawsuitArcturus sues AbbVie and Capstan over trade secrets, and Capstan counterclaims
PepGen PEPGSecurities class actionPepGen reports its securities class action and shareholder demand are over
Verrica Pharmaceuticals VRCASecurities class actionVerrica agrees in principle to settle 2022 securities class action over YCANTH
Perrigo Company PRGOSecurities class actionPerrigo faces New York securities class action over infant formula statements
BioAge Labs BIOASecurities class actionBioAge faces Ninth Circuit appeal of dismissed IPO securities class action
Geron GERNSecurities class actionGeron faces Rytelo securities class action and four derivative suits
Revolution Medicines RVMDMerger or deal suitRevolution Medicines reports final judgment in Delaware suit over EQRx merger
Context Therapeutics CNTXOther lawsuitContext Therapeutics closes Delaware suit over three-year director terms; $850,000 fee paid
Amgen AMGNSecurities class actionAmgen agrees to settle Roofers securities class action over IRS tax disclosures
Amgen AMGNSecurities class actionAmgen's ChemoCentryx securities class action settlement gets preliminary approval
BioCryst Pharmaceuticals BCRXPatent caseBioCryst sues Annora, Hetero and Camber in Delaware over generic ORLADEYO
Recursion Pharmaceuticals RXRXSecurities class actionRecursion and its lab landlord remain in Utah court over lease construction claims
ACADIA Pharmaceuticals ACADPatent caseAcadia awaits Federal Circuit ruling in Nuplazid patent suits; Zydus trial set for Nov. 2
Mirum Pharmaceuticals MIRMPatent caseMirum sues Sandoz, Hetero, Biophore and Zydus in Delaware over generic Livmarli; trial set for 2028
Niagen Bioscience NAGESecurities class actionNiagen Bioscience details consumer class actions, Thorne suit and Elysium fee appeal
Arrowhead Pharmaceuticals ARWRPatent caseArrowhead still defending Ionis patent suit over plozasiran after Delaware case was dismissed
OnKure Therapeutics OKURMerger or deal suitOnKure says plaintiffs have not pursued two New York suits over its Reneo merger proxy
Krystal Biotech KRYSDerivative suitKrystal Biotech reports DOJ subpoenas on VYJUVEK testing program, director pay suit settlement
Krystal Biotech KRYSPatent caseKrystal Biotech sued in Delaware over inventorship of two KB407 cystic fibrosis patents
Supernus Pharmaceuticals SUPNOther lawsuitSupernus faces January 2027 APOKYN antitrust trial; related insurance suits pending
Ocular Therapeutix OCULOther lawsuitOcular Therapeutix faces EyePoint defamation suit; injunction ruling still pending
Organon & Co. OGNSecurities class actionOrganon faces securities class action over dividend statements and a merger proxy suit
Bristol-Myers Squibb BMYSecurities class actionBristol Myers Squibb details Texas Plavix suit, Arkansas 340B complaint and Celgene settlement
Bristol-Myers Squibb BMYPatent caseBristol Myers Squibb sues seven generic drugmakers in Delaware over Camzyos patents
Baxter International BAXSecurities class actionBaxter faces two securities class actions and a derivative suit over Novum LVP statements
Baxter International BAXSecurities class actionBaxter's Hillrom unit faces Linet antitrust suit, a bed-buyer appeal and two DOJ requests
Alkermes ALKSPatent caseAlkermes sues Teva, Apotex and MSN over proposed generic Lybalvi
Alkermes ALKSSecurities class actionAlkermes faces direct-purchaser antitrust class action over Vivitrol patent
Summit Therapeutics SMMTDerivative suitSummit Therapeutics derivative suit over $520 million Duggan notes ends in voluntary dismissal
Evommune EVMNSEC or regulatorEvommune CFO agrees to return $10,160 short-swing profit after July share purchase
Silexion Therapeutics SLXNMerger or deal suitFormer SPAC sponsor sues Silexion in Tel Aviv over note conversions
Heron Therapeutics HRTXPatent caseDelaware court holds Heron CINVANTI patent claims invalid; Heron plans appeal
Cardiff Oncology CRDFPatent caseCardiff Oncology disputes Nerviano's termination of 2017 license agreement
SpyGlass Pharma, GLAUKOS SGPGKOSOther lawsuitSpyGlass countersues Glaukos in trade-secret case; trial moved to January 2027
Capricor Therapeutics CAPROther lawsuitCapricor sues Nippon Shinyaku and NS Pharma over Deramiocel U.S. distribution agreement
Fennec Pharmaceuticals FENCPatent caseFennec Pharmaceuticals settles PEDMARK patent litigation with Cipla
Arbutus Biopharma ABUSPatent caseArbutus and Genevant settle Moderna LNP patent litigation, $950.0 million due by July 8, 2026
Climb Bio CLYMOther lawsuitClimb Bio sues Alumis and Acelyrin over $3 million budoprutug milestone payment
Filana Therapeutics FLNASecurities class actionCassava Sciences (now Filana Therapeutics) agrees to $31.25 million class action settlement
AnaptysBio ANABOther lawsuitAnaptysBio sues Tesaro and GSK in Delaware Chancery Court over Jemperli collaboration
Allogene Therapeutics ALLOPatent caseAllogene discloses Factor Bioscience patent suit against licensor Cellectis; it is not a party
Enanta Pharmaceuticals ENTAPatent caseEnanta files patent infringement suit against Pfizer over Paxlovid in EU Unified Patent Court
Unicycive Therapeutics UNCYSecurities class actionUnicycive discloses securities class action over oxylanthanum carbonate statements
ImmunityBio IBRXDerivative suitImmunityBio gets preliminary court approval of shareholder derivative lawsuit settlement
Protalix BioTherapeutics, Inc. (DE) PLXSecurities class actionProtalix says Delaware stockholder class action over bylaws is dismissed, $160,000 in counsel fees
Cell Source CLCSOther lawsuitCell Source auditor Marcum resigns after CBIZ takes over its attest business
Harmony Biosciences Holdings HRMYPatent caseHarmony Biosciences settles WAKIX patent suit with Lupin, generic entry set for 2030
Taysha Gene Therapies TSHAOther lawsuitTaysha Gene Therapies prices public offering of 46,868,687 shares and pre-funded warrants at $2.75
Emergent BioSolutions EBSDerivative suitEmergent BioSolutions derivative lawsuit settlement gets preliminary court approval
ACADIA Pharmaceuticals ACADPatent caseAcadia Pharmaceuticals wins Delaware ruling on NUPLAZID formulation patent
Liquidia LQDAPatent caseUnited Therapeutics files patent infringement suit against Liquidia over YUTREPIA
Arbutus Biopharma ABUSPatent caseArbutus says court moved Moderna patent trial to September 29, 2025
Liquidia LQDAOther lawsuitCourt denies Liquidia's challenge to FDA exclusivity for Tyvaso DPI

How this tracker works

We add a case when a company discloses it in an SEC filing, when a court record or SEC release names it, or when a law firm announces a suit that has actually been filed, with a court and case number. Investigation notices with no filed case are left out. Law-firm claims are allegations, not findings. Every row links our story, and every story links the filing, court record or release it is based on. Something missing or wrong? Tell the editors.

News, not investment advice. How we work.

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.